Clinical dilemma of mood stabilizer augmentation in treatment-resistant schizophrenia with residual phase: A case report of valproate-associated hypoglycemia and cytopenia, and subsequent lithium response
{{output}}
Background: Mood stabilizer augmentation is frequently used in treatment-resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient... ...
